This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| A. Classification codes | ICD-10 C44 (C44.0-C44.9 by site; includes basal cell carcinoma, squamous cell carcinoma, sebaceous carcinoma, sweat gland carcinoma, etc.) |
| B. Synonyms | Skin cancer, non-melanoma skin cancer (NMSC), basal cell carcinoma (BCC), squamous cell carcinoma (SCC), malignant cutaneous adnexal tumors, Merkel cell carcinoma |
| C. Adult onset | Very high — occurs mainly in older adults aged 50 and above; most common in those aged 70 and above in Korea |
| Special Copayment Reduction | V193 · 5 years from the cancer patient registration date · 5% copayment |
| 1. History | History of non-melanoma skin cancer; establishment of the epidemiology of its association with ultraviolet radiation; 7-fold increase in skin cancer in Korea (1999→2019); development of Mohs surgery |
| 2. Causes | Ultraviolet radiation (UV-A, UV-B); chronic cumulative UV damage; immunosuppression; HPV; arsenic exposure; radiation; history of PUVA therapy |
| 3. Genetics | PTCH1/PTCH2 (BCC, hedgehog pathway); TP53, CDKN2A (SCC); SMAD4 (BCC metastasis); MCPyV (Merkel cell carcinoma) |
| 4. Epidemiology | 7-fold increase in NMSC in Korea over 20 years; BCC most common (46%); most frequent in those aged 70 and above; predilection for the head and neck |
| 5. Pathophysiology | UV → damage to PTCH1 in the hedgehog pathway (BCC); UV → TP53 C→T mutation → SCC; SCC arising in chronic inflammation and scars |
| 6. Symptoms | BCC: pearly translucent nodule, ulceration; SCC: keratotic nodule, ulcer, arising in chronic skin lesions; wounds that do not heal well |
| 7. Signs | Pearly lustrous nodule (BCC); keratotic mass/ulcer (SCC); abnormal dermoscopic findings; lymphadenopathy (when metastatic) |
| 8. Screening | Regular full-body skin examination; dermatology follow-up of high-risk groups; skin monitoring of immunosuppressed patients; HPV vaccination |
| 9. Diagnosis | Clinical and dermoscopic examination; punch biopsy or excisional biopsy; pathology (histologic type, depth of invasion, margins); PD-L1 testing (Merkel cell carcinoma) |
| 10. Treatment | Mohs micrographic surgery (Mohs surgery); wide excision; radiotherapy; vismodegib (BCC); cemiplimab/pembrolizumab (SCC); avelumab (Merkel cell carcinoma) |
| 11. Prognosis | BCC 5-year survival over 95% (metastasis rare); SCC metastasis 5-15% with high-risk features; Merkel cell carcinoma metastasis 30-40% |
| 12. Prevention | Sun protection, HPV vaccination, minimizing immunosuppression, preventing arsenic exposure, treating early lesions, regular checkups |
| 13. References | PMC paper on NMSC epidemiology in Korea, NCCN skin cancer guidelines, Korean Dermatological Association, literature on Mohs surgery |
ICD-10 C44 covers other malignant neoplasms of skin excluding melanoma (C43), and the most common clinically are basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). These are collectively called non-melanoma skin cancer (NMSC) and are the most common malignancies worldwide.
The historical description of basal cell carcinoma began in 1827 when Jacob reported an ulcerative lesion occurring around the orbit ("Jacob's ulcer"). In 1903, Krompecher first systematically described a distinctive skin tumor originating from basal cells, and the name "basal cell carcinoma" became established. Squamous cell carcinoma is associated with Pott's discovery in 1775 that scrotal cancer occurred in clusters among chimney sweeps, the first description of a link between an occupational carcinogen (soot) and cancer.
The association between ultraviolet radiation and skin cancer was established through epidemiological studies from the early 20th century, and the observation of a high incidence of head and neck skin cancer in outdoor workers was an important clue. Mohs micrographic surgery, developed in the 1930s by the American surgeon Frederic E. Mohs, is an innovative surgical technique that secures complete margins while minimizing skin defects. It is currently used as the gold standard treatment for BCC and SCC of the head and neck and the digits.
The epidemiology of NMSC in Korea is undergoing rapid change. Between 1999 and 2019, the number of NMSC cases in Korea increased more than about 7-fold, which is analyzed as due to a combination of factors such as population aging, increased outdoor activity, and increased ultraviolet exposure.
Chronic cumulative ultraviolet damage is the most important risk factor for both BCC and SCC. BCC is more strongly associated with intermittent high-intensity UV exposure (sunburn), and SCC with continuous chronic cumulative UV exposure. UV-B (280-315nm) directly damages DNA, causing C→T or CC→TT mutations (UV signature), which lead to inactivation of tumor suppressor genes such as TP53 and PTCH1. UV-A also contributes to skin cancer development through oxidative DNA damage. PUVA therapy (psoralen + UV-A) is used to treat psoriasis, but long-term treatment is known to increase SCC risk by tens of times.
In patients receiving immunosuppressive therapy after kidney transplantation, the risk of SCC increases 60-250-fold and the risk of BCC 10-fold. Skin cancer risk is also markedly elevated in patients with HIV/AIDS. In immunosuppressed states, cutaneous HPV infection may contribute to skin cancer development.
HPV (Human papillomavirus), particularly beta-type HPV, is being studied for its involvement in SCC development in immunosuppressed patients. Arsenic exposure (contaminated groundwater, some medications) increases the risk of SCC, and chronic actinic keratosis is a precursor lesion of SCC. Chronic wounds, burn scars, and chronic radiation dermatitis can also be settings for SCC development. In the genetic disorders xeroderma pigmentosum and Gorlin syndrome (PTCH1 variant), the risk of skin cancer is extremely increased.
The most central genetic abnormality of BCC is aberrant activation of the Hedgehog signaling pathway. PTCH1 (Patched-1 tumor suppressor gene) mutations (about 70-90%) are the most common; they release the inhibition of SMO (Smoothened), so nuclear translocation of GLI transcription factors and target gene expression are constitutively activated. PTCH2 and SMO activating mutations are also observed in BCC. TP53 mutations are found in about 50% of BCCs and, together with PTCH1 mutations, show a UV-specific mutation pattern. Hereditary basal cell carcinoma syndrome (Gorlin syndrome) is caused by germline PTCH1 variants.
In SCC, TP53 mutations are the most common (about 60-80%), characterized by a UV-specific C→T mutation pattern. CDKN2A (p16) deletion and RAS pathway (HRAS, KRAS) activating mutations are also observed. High TMB (tumor mutational burden) is a feature of SCC and increases responsiveness to immune checkpoint inhibitor therapy. When PD-L1 expression is high, it becomes a target for cemiplimab or pembrolizumab treatment.
In about 80% of Merkel cell carcinoma (MCC), the Merkel cell polyomavirus (MCPyV) genome is integrated into tumor cells, and MCPyV-positive MCC has a relatively better prognosis than negative MCC. In MCPyV-negative MCC, UV-induced TP53 mutations and RB1 mutations are more common, and TMB is high.
NMSC is the most common malignancy worldwide. In the United States, about 4 million NMSC cases are diagnosed annually, more than the number of all other malignancies combined.
The epidemiology of NMSC in Korea has changed rapidly over the past 20 years. Between 1999 and 2019, the total number of NMSC cases increased more than 7-fold; in particular, BCC increased about 8-fold, from 488 cases (1999) to 3,908 cases (2019). SCC increased by an average of about 5.1% per year. In Korea, the histologic distribution of NMSC is BCC at about 46%, the most common, SCC at about 19%, melanoma (C43) at about 7%, and the remainder other rare skin malignancies.
In Korea, NMSC occurs most frequently in those aged 70 and above, and in incidence data for 1999-2019 the frequency was highest in those aged 70 and older. The most common site is the head and neck (especially around the nose, cheeks, and ears), corresponding to the areas with the most sun exposure. SCC occurs somewhat more in men than in women, but BCC shows little sex difference.
BCC originates from basal keratinocytes or the lower epithelium of hair follicles. UV-induced PTCH1 mutation is the core mechanism. Normally PTCH1 inhibits SMO to block Hedgehog signaling, but with PTCH1 inactivation SMO is constitutively activated, and downstream GLI transcription factors move to the nucleus and overexpress genes for cell proliferation, inhibition of differentiation, and inhibition of apoptosis. This leads to abnormal proliferation of basal cells and tumor formation. Vismodegib and sonidegib are Hedgehog pathway inhibitors targeting SMO and are used to treat advanced and metastatic BCC.
SCC originates from keratinocytes and undergoes a multistep carcinogenic process due to chronic cumulative UV damage. It follows the stages of normal skin → actinic keratosis → carcinoma in situ (SCC in situ, Bowen disease) → invasive SCC. TP53 mutation is the key event occurring earliest; UV-specific C→T mutations abolish p53 function, preventing the death of DNA-damaged cells and causing accumulation of abnormal cells. Subsequently, CDKN2A loss, RAS activation, and PI3K pathway abnormalities contribute to progressive tumor formation. In immunosuppressed patients, HPV infection promotes SCC development by inhibiting the functions of p53 and pRb through the E6/E7 proteins.
On inspection, a nodule with a pearly, lustrous translucent border is observed. On dermoscopy, arborizing vessels (branching telangiectasia) are identified as a specific finding of BCC. In pigmented BCC, irregular blue-gray ovoid nests and a multilobular pattern are characteristic on dermoscopy. In morpheaform BCC, the lesion extent is clinically underestimated, so the risk of incomplete excision at surgery is high.
In advanced SCC, regional lymphadenopathy may be palpable (metastasis rate 3-5%, higher with high-risk features). On dermoscopy, SCC shows atypical vascular patterns (hairpin vessels, glomerular vessels) and surface keratinization. When perineural invasion occurs, sensory abnormalities or pain appear along the distribution of the affected nerve. Actinic keratosis is characterized by a strawberry pattern on dermoscopy.
Merkel cell carcinoma appears as a rapidly growing flesh-colored or red nodule and shows nonspecific but vascular-rich findings on dermoscopy. Because regional lymph node metastasis is common (about 30-40%), lymphadenopathy is sometimes already palpable at diagnosis.
National standard screening for NMSC is not recommended. However, regular skin examination is important in the following high-risk groups:
HPV vaccination, in addition to preventing HPV-related cervical cancer and anogenital cancers, may also help prevent HPV-related cutaneous SCC. HPV vaccination is strongly recommended especially in immunosuppressed patients.
Through clinical examination and dermoscopy, benign and malignant lesions are differentiated and biopsy targets are selected. Dermoscopy increases sensitivity and specificity in differentiating basal cell carcinoma, squamous cell carcinoma, and melanoma, contributing to reducing unnecessary biopsies. Reflectance confocal microscopy is a noninvasive deep skin examination method being gradually introduced into clinical practice.
Punch biopsy or excisional biopsy is the standard diagnostic method. For BCC, shave biopsy is also used. Biopsy to check for transformation to SCC in actinic keratosis is also important. Because Merkel cell carcinoma is difficult to diagnose clinically, active biopsy of suspicious lesions is recommended.
The pathology report includes the histologic subtype (nodular, morpheaform, infiltrative, etc.), depth of invasion, presence of perineural, lymphatic, and vascular invasion, and margin status. In high-risk SCC, sentinel lymph node biopsy (SLNB) is considered. In Merkel cell carcinoma, MCPyV antibody testing and CK20 immunohistochemistry (+) and TTF-1 (-) findings are used for diagnosis. PD-L1 expression testing is referenced when applying cemiplimab or pembrolizumab.
It is the gold standard treatment for BCC and SCC at functionally and cosmetically important sites such as the head and neck, digits, and genitalia. The tumor is removed in thin layers while 100% of the margins are examined immediately on frozen sections, and if residual tumor is present, only that area is additionally removed. Preservation of normal tissue is maximized and the recurrence rate is the lowest (BCC less than 1%, SCC 3-5%).
Wide excision is used for sites where Mohs surgery is not applied or for large tumors. The standard margin for BCC is 4-6mm, and for SCC 4-6mm (low risk) or 10mm (high risk).
Radiotherapy is used in patients who cannot undergo surgery or when margins are positive after surgery. Photodynamic therapy (PDT), 5-FU cream, and imiquimod cream are used to treat superficial BCC and actinic keratosis. Cryotherapy is used for small, superficial lesions.
| Indication | Drug | Mechanism |
|---|---|---|
| Advanced/metastatic BCC | Vismodegib, sonidegib | SMO (Hedgehog pathway) inhibition |
| Advanced/metastatic SCC | Cemiplimab, pembrolizumab | Anti-PD-1 immune checkpoint inhibitor |
| Merkel cell carcinoma (MCC) | Avelumab, pembrolizumab | Anti-PD-L1/anti-PD-1 immunotherapy |
| SCC in organ transplant recipients | Acitretin | Retinoid chemoprevention |
Most NMSCs have a very good prognosis when detected and treated early.